Results 21 to 30 of about 1,995 (245)

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination [PDF]

Journal of Infectious Diseases
Abstract Background We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003. Methods Children 4–16 years of age were randomized 2:1 to ...
Shibadas Biswal, Pope Kosalaraksa, Veerachai Watanaveeradej   +2 more
exaly   +4 more sources

Travel medicine providers’ opinions on the dengue vaccine TAK-003 as a travel vaccine and the need for decision-support information and materials before its launch in Japan [PDF]

Human Vaccines & Immunotherapeutics
TAK-003 is a dengue vaccine introduced in dengue-endemic countries and considered for travelers. Although not yet approved in Japan, inquiries from travelers are increasing.
Atsuko Fukunishi, Masaki Machida, Shinji Fukushima, Shigeru Inoue   +3 more
doaj   +2 more sources

Efficacy of Live Attenuated Dengue Vaccines: CYD-TDV, TDV (TAK-003), and TV003/TV005

Folia Medica Indonesiana, 2021
Highlight: • Differences in the efficacy of CYD-TDV versus the other TAK-003 and TV003/TV005 were discussed. • One licensed dengue vaccine is CYD-TDV (Dengvaxia).
Yoseph Jeffry Hertanto, Bernadette Dian Novita   +1 more
doaj   +4 more sources

BRIDGING THE IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) FROM CHILDREN AND ADOLESCENTS TO ADULTS

International Journal of Infectious Diseases, 2023
Intro: Dengue efficacy studies are not feasible in dengue non-endemic countries. For TAK-003, we present an immunobridging analysis to infer vaccine efficacy as determined in the DEN-301 phase 3 efficacy trial conducted in children and adolescents from ...
C. Halim, V. Tricou, F. Nordio, N. Folschweiller   +3 more
doaj   +2 more sources

Reply to: Letter to Editor “Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine”

Expert Review of Vaccines
Zeb Youard
exaly   +5 more sources

Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data [PDF]

Virology Journal
Background and objectives Dengue is one of the fastest spreading arboviral infection with no specific antiviral treatment, making vaccination a significant preventive approach.
Ravi Kant, Anushka Singh, A. Babar Ali, Shweta Nagre, Nirmal Kumar Ganguly, Rashmi Rana   +5 more
doaj   +2 more sources

Correction: Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand. [PDF]

PLoS Medicine
[This corrects the article DOI: 10.1371/journal.pmed.1004631.].
Jing Shen, Elizaveta Kharitonova, Anna Tytula, Justyna Zawieja, Samuel Aballea, Shibadas Biswal, Mayuri Sharma, Supattra Rungmaitree, Rosarin Sruamsiri, Derek Wallace, Riona Hanley   +10 more
doaj   +2 more sources

State of the Art on Vaccine Development Against Dengue Infection: Scoping Review of the Literature [PDF]

Infectious Disease Reports
Background: Dengue virus infection is a significant challenge for global health, with 100 million symptomatic cases, 2.3 million DALYs and 20,000 deaths annually.
Davide Marangoni, Anna Barbiero, Michele Spinicci, Alessandro Bartoloni, Andrea Rossanese, Paolo Bonanni, Lorenzo Zammarchi   +6 more
doaj   +2 more sources

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue. [PDF]

Am J Trop Med Hyg, 2023
ABSTRACT. In the pivotal phase 3 efficacy trial (NCT02747927) of the TAK-003 dengue vaccine, 5 of 13,380 TAK-003 recipients and 13 of 6,687 placebo recipients experienced two episodes of symptomatic dengue between the first dose and the end of the study, ∼57 months later (patients received the second dose 3 months after the first dose).
Sáez-Llorens X, Biswal S, Borja-Tabora C, Fernando L, Liu M, Wallace D, Folschweiller N, Reynales H, LeFevre I, TIDES Study Group.   +9 more
europepmc   +3 more sources

Immunogenicity of a Live Dengue Vaccine (TAK-003). [PDF]

J Infect Dis, 2022
de Silva A, White L.
europepmc   +3 more sources